| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Alisol B 23-acetate primarily targets the farnesoid X receptor (FXR). It acts as an FXR activator, which mediates its hepatoprotective effects by regulating the expression of transporters and enzymes involved in bile acid homeostasis.
|
|---|---|
| ln Vitro |
In cell-free or receptor-binding assays, Alisol B 23-acetate's activity is evaluated by its ability to activate FXR. This is typically measured using a luciferase reporter assay in HepG2 cells, where the compound's effect on FXR-mediated transcription is quantified in a dose-dependent manner. In vitro studies show that Alisol B 23-acetate induces apoptosis in human lung cancer cells via the mitochondrial pathway and in human prostate cancer cells. It activates FXR in a dose-dependent manner in HepG2 cells as shown by luciferase reporter assays. It also promotes hepatocyte proliferation through FXR activation.
|
| ln Vivo |
In vivo, Alisol B 23-acetate protects against CCl4-induced hepatotoxicity and ANIT-induced cholestasis in mice via FXR activation. It reduces hepatic bile acids by decreasing uptake transporters (Ntcp) and synthetic enzymes (Cyp7a1, Cyp8b1) and increasing efflux transporters (Bsep, Mrp2). It also induces STAT3 phosphorylation and target genes, reducing hepatocyte apoptosis.
|
| Enzyme Assay |
In vitro FXR activation assays are performed in HepG2 cells transfected with an FXR-responsive luciferase reporter gene. Cells are treated with various concentrations of Alisol B 23-acetate, and luciferase activity is measured to determine the compound's potency in activating FXR-mediated transcription.
|
| Cell Assay |
HepG2 cells are cultured and transfected with FXR and a luciferase reporter plasmid. After treatment with Alisol B 23-acetate for a specified period, cells are lysed, and luciferase activity is measured. The EC50 for FXR activation is determined from the dose-response curve. Cell viability and apoptosis are also assessed in cancer cell lines.
|
| Animal Protocol |
In mouse models, Alisol B 23-acetate is administered orally or intraperitoneally. Hepatotoxicity is induced by CCl4 or ANIT. Liver histology, serum biomarkers (ALT, AST, bile acids), and expression of FXR target genes are analyzed. The protective effect is evaluated by comparing these parameters between treated and untreated groups.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Alisol B 23-acetate are not extensively reported. As a natural triterpenoid, its oral bioavailability may be limited. Studies focus on its tissue distribution and metabolic stability. Further research is needed to fully characterize its ADME profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Alisol B 23-acetate is limited. It is generally considered safe for research use at standard doses. High doses may cause cytotoxicity, as it induces apoptosis in cancer cells. Its hepatoprotective effects suggest a favorable safety profile in the liver at therapeutic doses.
|
| References |
|
| Additional Infomation |
Alisol B acetate is a triterpenoid compound. It has been reported to be present in Alisma, Alisma lanceolatum, and other organisms with relevant data. See also: root (part) of Alisma plantago-aquatica subsp. orientale.
Alisol B 23-acetate is a natural product with hepatoprotective, anti-inflammatory, and anticancer activities. It is a valuable tool for studying FXR-mediated gene regulation and bile acid homeostasis. It is not an approved drug but is used in preclinical research for its potential therapeutic applications. |
| Molecular Formula |
C32H50O5
|
|---|---|
| Molecular Weight |
514.7364
|
| Exact Mass |
514.365
|
| CAS # |
26575-95-1
|
| Related CAS # |
Alisol B;18649-93-9
|
| PubChem CID |
14036811
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
590.7±50.0 °C at 760 mmHg
|
| Flash Point |
179.9±23.6 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
5.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](C[C@@H]([C@@H]1C(O1)(C)C)OC(=O)C)C2=C3C[C@@H]([C@H]4[C@]5(CCC(=O)C([C@@H]5CC[C@@]4([C@]3(CC2)C)C)(C)C)C)O
|
| InChi Key |
NLOAQXKIIGTTRE-JSWHPQHOSA-N
|
| InChi Code |
InChI=1S/C32H50O5/c1-18(16-23(36-19(2)33)27-29(5,6)37-27)20-10-14-31(8)21(20)17-22(34)26-30(7)13-12-25(35)28(3,4)24(30)11-15-32(26,31)9/h18,22-24,26-27,34H,10-17H2,1-9H3/t18-,22+,23+,24+,26+,27-,30+,31+,32+/m1/s1
|
| Chemical Name |
[(1S,3R)-1-[(2R)-3,3-dimethyloxiran-2-yl]-3-[(5R,8S,9S,10S,11S,14R)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]butyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~97.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9427 mL | 9.7136 mL | 19.4273 mL | |
| 5 mM | 0.3885 mL | 1.9427 mL | 3.8855 mL | |
| 10 mM | 0.1943 mL | 0.9714 mL | 1.9427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
